Completed PHASE4 INTERVENTIONAL NCT00262548

C-Reactive Protein (CRP) in Obese Diabetic Women

Interventions Study for the Control of Diabetes Mellitus Type 2 in Obese Women

Sponsor: AstraZeneca

Interventions Rosuvastatin; improvement of lipid profile

Updated 5 times since 2017 Last updated: Aug 24, 2007 Started: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Diabetes Mellitus, Type 2 and is currently completed. AstraZeneca leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Mexican National Institute of Public Health

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cuernavaca, Mexico